- Home
- WHWK vs LENZ Comparison
WHWK vs LENZ Comparison
Compare WHWK & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | LENZ |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 278.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHWK | LENZ |
|---|---|---|
| Price | $4.10 | $7.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.50 | ★ $44.00 |
| AVG Volume (30 Days) | 317.4K | ★ 841.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $6.61 |
| 52 Week High | $5.50 | $50.19 |
Technical Indicators
Market Signals| Indicator | WHWK | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 35.04 |
| Support Level | $3.72 | N/A |
| Resistance Level | $4.38 | $10.42 |
| Average True Range (ATR) | 0.35 | 0.64 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 23.56 | 13.68 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.